Logical Therapeutics' Check List: Finish Phase II Studies For Naproxen Pro-Drug, Find A Buyer
This article was originally published in The Pink Sheet Daily
Executive Summary
Logical hopes Phase II results for its lead anti-inflammatory drug will open the door for a potential buyer.
You may also be interested in...
PregLem Weighs Financing Options Well Ahead Of Uterine Fibroid Drug Launch
Esmya, an oral therapy being developed for symptomatic uterine fibroids, showed non-inferiority to GnRH agonists in a Phase III study.
Logical Therapeutics Inc.
The gastrointestinal problems linked to NSAIDS are certainly no secret: the ability to mitigate them turned Vioxx into a blockbuster drug, that is, until it was pulled from the market because of cardiovascular problems. Now, Logical Therapeutics in-licensed rights to a pro-drug of naproxen that it thinks will have the GI-safety profile of Vioxx and the cardiovascular safety profile of naproxen.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.